

IN THE CLAIMS:

Claims 1-67, 76, and 77 were previously cancelled. Claims 70-74 and 78 are cancelled herein. Claims 68, 69, and 75 have been amended herein. New claim 79 is presented herein. All of the pending claims are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

Listing of the Claims:

1.-67. (Cancelled).

68. (Currently amended) A method for stimulating an immune response to a tumor antigen, said the method comprising administering to an individual ~~who has been exposed to or is at risk of exposure to a first antigen in need thereof~~ a composition comprising a conjugate of the ~~first~~ tumor antigen and ~~at least one second antigen, wherein the at least one second antigen comprises~~ at least one non-sialylated Lewis x antigen.

69. (Currently amended) The method according to claim 68, wherein ~~said first~~ the tumor antigen is a peptide or glycolipid capable of being presented in the context of MHC class I or class II or C1b.

70.-74. (Cancelled).

75. The method according to claim ~~[[68]]~~ 79, wherein said C-type lectin receptor is DC-SIGN.

76.-78. (Cancelled).

79. (New) The method according to claim 68, wherein the non-sialylated Lewis x antigen targets the tumor antigen to a C-type lectin receptor on an antigen presenting cell of said individual.